Unison Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 26-07-2024
- Paid Up Capital ₹ 0.10 M
as on 26-07-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -16.18%
(FY 2023)
- Ebitda -16.18%
(FY 2023)
- Net Worth -41.86%
(FY 2023)
- Total Assets -0.27%
(FY 2023)
About Unison Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nitin Shah and Bhagyesh Shah serve as directors at the Company.
- CIN/LLPIN
U24230GJ2012PTC072070
- Company No.
072070
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Sep 2012
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Unison Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Shah  | Director | 24-Sep-2012 | Current |
| Bhagyesh Shah | Director | 24-Sep-2012 | Current |
Financial Performance of Unison Remedies.
Unison Remedies Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16.18% decrease in profit. The company's net worth observed a substantial decline by a decrease of 41.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unison Remedies?
In 2023, Unison Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unison Pharmaceuticals Private LimitedActive 23 years 6 monthsNitin Shah and Bhagyesh Shah are mutual person
- Cosmecia Healthcare Private LimitedActive 3 months 26 days
Nitin Shah and Bhagyesh Shah are mutual person
- Unison Bioscience Private LimitedActive 12 years 29 days
Nitin Shah and Bhagyesh Shah are mutual person
- Unison Life Sciences Private LimitedActive 12 years 2 months
Nitin Shah and Bhagyesh Shah are mutual person
- Unison Nutraceuticals Private LimitedActive 11 years 2 months
Nitin Shah and Bhagyesh Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unison Remedies?
Unlock and access historical data on people associated with Unison Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unison Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unison Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
